Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

DCG(I) bans 344 drugs constituting fixed dose combinations, but will it hold?

2016-03-21 financialexpress
Abhijeet Das, Senior Associate, Singhania and Partners, opines that there are multiple fronts on which the aggrieved pharma companies can contest the ban

Inhalation and Nasal Spray Generic Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

2016-03-01 prnewswire
NEW YORK, Feb. 29, 2016 /PRNewswire/ -- This report on the inhalation and nasal spray generic drugs market studies...


2016-02-27 caselaw.findlaw
FindLaw's searchable database of United States Sixth Circuit decisions since

Neutral rating on Sun Pharma: Q3FY16 driven by Taro

2016-02-21 financialexpress
Strong performance of Taro was the key contributor during the quarter. Higher other income and lower tax rate resulted in PAT being 4% higher than our estimates.

Alstom, Cipla among 10 FDI proposals worth ₹607 crore cleared

2016-02-15 thehindubusinessline
8 proposals deferred, 5 rejected by Foreign Investment Promotion Board

Corporate Results 2016

MUMBAI : Indian Bank is expected to report a 14% year-on-year fall in net profit for Oct-Dec at 2.38 bln rupees due to a likely rise in provisions,according to the average of the estimates of four brokerage houses.The public sector bank is scheduled to announce its earnings for Oct-Decon Thursday.Sequentially, the bottomline is seen falling 36%.”Expect 17% YoY growth in opex (operational expenditure), largely on a lower base (-5% YoY in the year-ago period)… elevated credit costs areexpected to result in PAT de-growth of (nearly) 35% YoY.

Cipla Q3 net profit rises 4.68% to Rs 343 cr

2016-02-10 business-standard
Net sales during the period under review stood at Rs 3,027.26 crore, up 15.33%.

Cipla, Ambuja Cement, Kalpataru Power and GMR Infra: Check out the expectations

2016-02-10 indiainfoline
Cipla Ltd, one of the leading drug makers in India, will announce its financial results on February 10. IIFL forecasts the company’s net revenue for Q3 FY16 to increase to Rs. 3,403 crore, growing at a rate of 23.1% yoy; however, it is likely to drop 1.4% qoq.

Y.K. Hamied to up stake in Cipla by 5%

2016-01-21 livemint
Hamied, who holds 15.54% in Cipla, will increase his stake to 20.76% once the proposal is approved

Cipla gets CCI nod for investment by FIL Capital

2016-01-21 moneycontrol
The Competition Commission of India has granted approval to the proposed investment by FIL Capital Investments (Mauritius) II Limited in Cipla Health Limited, subsidiary of the company, Cipla Ltd said in a regulatory filing. ..

Natco signs pact to make and sell hepatitis-C drug in 112 countries

2016-01-21 livemint
Natco signed a pact with Medicines Patent Pool and Bristol-Myers Squibb to make and sell identical version of Daclatasvir, a drug used to treat hepatitis C

Pharma Packaging Trends in 2016

2016-01-20 financialexpress
Securing the supply chain, environmental sustainability and updation of technology infrastructure will be the buzzwords. By Usha Sharma

Emerging Markets: Health Care and Pharma

2016-01-14 nasdaq
Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!

Cipla sets up 6-member leadership team

2016-01-07 business-standard
Drug major Cipla today announced the creation of a 6-member 'Management Council' that will be the apex executive leadership team for the company. Headed by Subhanu Saxena, Managing Director & Global Chief Executive Officer, the council will

Cipla sets up 6-member leadership team

2016-01-07 moneycontrol
This is part of the company's ongoing transformation journey to simplify decision making and improve operational excellence, Cipla Ltd said in a statement. .. (0-1)